OA-48 Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (IKEMA): final overall survival analysis — Kwee Yong (2023) | RDL Network
OA-48 Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (IKEMA): final overall survival analysis
Ecenur Guder Arslan, Kwee Yong, T. John Martin, Meletios A Dimopoulos, Joseph Mıkhael, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martínez, Chang‐Ki Min, Philippe Moreau
Kwee Yong, T. John Martin, Meletios A Dimopoulos, Joseph Mıkhael, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martínez, Chang‐Ki Min, Luděk Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Marie‐Laure Risse, Philippe Moreau
Marcelo Capra, Thomas G. Martin, Philippe Moreau, Ross Baker, Luděk Pour, Chang‐Ki Min, Xavier Leleu, Mohamad Mohty, Marta Reinoso Segura, Mehmet Turgut, Richard LeBlanc, Marie‐Laure Risse, Laure Malinge, Sandrine Schwab, Meletios A Dimopoulos
Marcelo Capra, Thomas G. Martin, Philippe Moreau, Ross Baker, Luděk Pour, Chang‐Ki Min, Xavier Leleu, Mohamad Mohty, Marta Reinoso Segura, Mehmet Turgut, Richard LeBlanc, Marie‐Laure Risse, Laure Malinge, Sandrine Schwab, Meletios A Dimopoulos
Thomas G. Martin, Marcelo Capra, Mohamad Mohty, Kenshi Suzuki, Hang Quach, Michèle Cavo, Philippe Moreau, Meletios A Dimopoulos, Kwee Yong, Christina Tekle, Meredith C. Foster, Yvonne Barnes, Marie‐Laure Risse, Joseph Mıkhael
Discussion(0)
No comments yet. Be the first to comment.